
Cadre Holdings delivered strong Q3 results, with accelerating organic growth and improved margins while beating estimates. I have a small discomfort with capital allocation: buybacks, M&A, dividends, and rising debt outpace considerably cash generation. My 2028 price target is still $39, so the current potential return is less compelling. Long-term M&A thesis intact, but discipline needed.










